What Is Life Science Real Estate?
Life science real estate is laboratory and research space leased to biotechnology, pharmaceutical and research tenants, concentrated in clusters such as Boston-Cambridge, the San Francisco Bay Area and San Diego, with heavy mechanical systems, high ceilings and specialized fit-out that cost far more than office. The sector boomed with biotech funding from 2015 to 2021, drew a wave of speculative development and office conversions, and then faced rising vacancy as funding fell and that supply arrived.
| Item | Detail |
|---|---|
| Space | Wet labs with fume hoods, HVAC at 100% outside air, vibration control, chemical storage; typically 50% to 60% lab, the rest office |
| Clusters | Boston-Cambridge, South San Francisco and the Bay Area, San Diego, Research Triangle, Seattle, New York |
| Tenants | Venture-funded biotechs, pharmaceutical companies, academic institutions, contract research organizations |
| Cost | Fit-out of $300 to $600 a square foot, often shared between landlord and tenant |
| Cycle | Demand tracks biotech venture funding and IPOs; 2021 peak, 2022 to 2024 contraction |
| Tax | 39-year depreciation; lab systems on shorter schedules under Publication 946 |
How Does Life Science Real Estate Work?
The landlord builds or converts a building to lab standards, with the mechanical plant, floor loading and ceiling heights that research requires, and leases it under 7- to 10-year leases to tenants whose ability to pay depends on their funding: a pre-revenue biotech's lease is backed by its cash runway and venture investors, and a failed trial can end the tenant. Clusters matter because talent, universities and hospitals concentrate there, so rents in Cambridge reached levels that drew conversions of offices and new towers from 2019 to 2022, just as biotech funding and IPOs collapsed in 2022; vacancy in the major clusters rose from near zero to the high teens by 2024 and sublease space flooded the market. The Census construction data captured the building wave; IRS Publication 946 sets depreciation, with cost segregation moving lab systems to shorter lives; the sector's REITs report leasing, tenant funding and development pipelines.
Worked example. A 150,000 square foot lab building in a major cluster was fully leased at $95 a foot. Biotech funding falls, tenants fail or sublease, vacancy rises to 18% and market rent for the rest falls 15% at renewal. The lost gross rent, about $3.7 million a year, is worth $66,426,923 of value at a 6.5% cap rate, before the cost of re-leasing lab space to the next tenant. The landlord who signed the leases in 2021 priced a funding environment that lasted two more years. The inputs are illustrative numbers, not market data.
What Does Life Science Real Estate Cost?
Construction and fit-out far above office; tenant improvement allowances of $150 to $300 a foot; operating costs for intensive HVAC; leasing commissions; for conversions, the risk that the building cannot meet lab standards at the budgeted cost; management and development fees.
How Is Life Science Real Estate Taxed?
Rental income through REITs, partnerships or direct ownership; 39-year depreciation under Publication 946 with cost segregation for lab systems; tenant improvements depreciated over the lease or 39 years depending on ownership; passive activity rules under Publication 925; sale treatment under Publication 544.
What Are the Risks of Life Science Real Estate?
- Tenant credit tied to venture funding and clinical outcomes.
- Supply: the 2019 to 2023 development wave arrived into a funding downturn.
- Specialization: lab space is expensive to build and hard to convert back.
- Cluster concentration: the sector's value sits in a handful of metros.
Common misconception. Life science real estate is not office with better tenants. The tenants are among the riskiest in commercial property, funded by venture capital and dependent on trial results, and the space is among the most expensive to build and least flexible to re-lease; the sector's strong decade reflected a biotech funding boom, and its correction reflected the end of it.
Where Does Life Science Real Estate Fit?
Liquidity. Good for leased buildings in the major clusters in normal markets; poor for speculative and converted space in a downturn; through life science REITs, daily.
Who uses it. Real estate investors with expertise in the clusters and the ability to underwrite biotech tenants' funding; life science REITs for exposure with diversification across tenants and buildings.
Portfolio role. A specialized, cyclical component of a real estate allocation tied to biotech funding; sized small and held through REITs for most investors.